ArticleMedical oncology (Northwood, London, England)2026
Mesenchymal stromal cells regulate M2 macrophage polarization that promotes proliferation, migration, and invasion of renal cell carcinoma cells.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Accumulating evidence from studies in other tumour types suggests that mesenchymal stromal cells (MSCs) may influence macrophage polarization, but the underlying mechanisms in renal cell carcinoma (RCC) remain unclear. In this study, renal carcinoma-derived MSCs (RCC-MSCs) were isolated from the tumour tissue of a patient with clear cell renal cell carcinoma, and BM-MSC-derived MSC1 was included as an exploratory reversal model rather than as a biologically matched comparator. THP-1-derived macrophage models, together with co-culture assays, flow cytometry, Western blotting, quantitative real-time PCR, and ELISA, were used to evaluate macrophage phenotypes and cytokine secretion. Patient-derived RCC-MSCs from a single ccRCC specimen promoted M2-like macrophage polarization in vitro, and this effect was attenuated by NF-κB inhibition with pyrrolidine dithiocarbamate (PDTC). In turn, RCC-MSC-primed macrophages enhanced the growth, migration, and invasion of 786-O cells in vitro, whereas blockade of NF-κB attenuated these tumour-promoting effects. In an exploratory in vitro setting, BM-MSC-derived MSC1 favoured partial reprogramming of M2 macrophages toward an M1-like phenotype. Collectively, these findings suggest that patient-derived RCC-MSCs from a single ccRCC specimen may promote M2-like macrophage polarization through NF-κB-related signalling and enhance malignant phenotypes of 786-O cells in vitro, while BM-MSC-derived MSC1 supports the plasticity of macrophage polarization in an exploratory setting.
Indexed as
Identifiers
42565904What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.